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OBJECTIVE—Intestinal L-cells secrete the incretin glucagon-
like peptide-1 (GLP-1) in response to ingestion of nutrients,
especially long-chain fatty acids. The Gs-coupled receptor
GPR119 binds the long-chain fatty acid derivate oleoylethanol-
amide (OEA), and GPR119 agonists enhance GLP-1 secretion. We
therefore hypothesized that OEA stimulates GLP-1 release
through a GPR119-dependent mechanism.
RESEARCH DESIGN AND METHODS—Murine (m) GLUTag,
human (h) NCI-H716, and primary fetal rat intestinal L-cell
models were used for RT-PCR and for cAMP and GLP-1 radio-
immunoassay. Anesthetized rats received intravenous or in-
traileal OEA, and plasma bioactive GLP-1, insulin, and glucose
levels were determined by enzyme-linked immunosorbent assay
or glucose analyzer.
RESULTS—GPR119 messenger RNA was detected in all L-cell
models. OEA treatment (10 mol/l) of mGLUTag cells increased
cAMP levels (P  0.05) and GLP-1 secretion (P  0.001) in all
models, with desensitization of the secretory response at higher
concentrations. GLP-1 secretion was further enhanced by pre-
vention of OEA degradation using the fatty acid amide hydrolase
inhibitor, URB597 (P  0.05–0.001 vs. OEA alone), and was
abolished by H89-induced inhibition of protein kinase A. OEA-
induced cAMP levels and GLP-1 secretion were signiﬁcantly
reduced in mGLUTag cells transfected with GPR119-speciﬁc
small interfering RNA (P  0.05). Application of OEA (10 mol/l)
directly into the rat ileum, but not intravenously, increased
plasma bioactive GLP-1 levels in euglycemic animals by 1.5-fold
(P  0.05) and insulin levels by 3.9-fold (P  0.01) but only in the
presence of hyperglycemia.
CONCLUSIONS—The results of these studies demonstrate, for
the ﬁrst time, that OEA increases GLP-1 secretion from intestinal
L-cells through activation of the novel GPR119 fatty acid derivate
receptor in vitro and in vivo. Diabetes 58:1058–1066, 2009
G
lucagon-like peptide-1 (GLP-1) is an intestinal
hormone with potent insulinotropic effects that
are essential to the maintenance of normal
glucose homeostasis (1). In addition to glucose-
dependent stimulation of insulin secretion, GLP-1 shows
other favorable effects, increasing -cell proliferation in
rodents, as well as enhancing -cell survival in both rodent
and in human islets (2,3). Additionally, GLP-1 has been
shown to protect cardiomyocytes from ischemia, and
GLP-1 infusion improves cardiac function in patients with
heart failure (4,5). Finally, the central nervous system
effects of GLP-1 include inhibition of gastric emptying,
reduction of appetite, and promotion of satiety in humans
(6,7) and rodents (8,9). As a result of its potent antidiabe-
tes and anorexic effects, GLP-1 analogs and GLP-1 degra-
dation inhibitors have been successfully introduced to the
clinic for pharmacologic treatment of patients with type 2
diabetes (10).
While the biological effects of GLP-1 have been well
established, the mechanisms underlying GLP-1 secretion
are less well understood. GLP-1 is secreted from intestinal
endocrine L-cells, localized predominantly in the distal
ileum and colon (11). Rapid GLP-1 release after food
intake (12,13) may be regulated by afferent innervation by
the vagus nerve (14,15) as well as, in rodents, by proximal
gut hormones, such as glucose-dependent insulinotropic
peptide (GIP) from the duodenal K-cells (16). However,
L-cells also release GLP-1 in response to direct stimulation
by nutrients (16), such as carbohydrates and, most nota-
bly, fat (17,18). Monounsaturated long-chain fatty acids,
such as oleic acid, are strong stimulators of GLP-1 secre-
tion from the L-cells, both in vitro and in vivo, through a
signaling pathway that requires protein kinase C (PKC) 
(17,18). Additional studies have indicated roles for the
orphan G-protein–coupled receptors, GPR40 and GPR120,
in the response of the L-cell to saturated fat and -linolenic
acid, respectively (19,20). Very recently, the fatty acid
derivate receptor, GPR119, was also found to be expressed
in a highly tissue-speciﬁc fashion by the intestinal L-cell
and the pancreatic -cell (21,22). Furthermore, a GPR119-
speciﬁc pharmacological agonist was demonstrated to
increase the plasma levels of both GLP-1 and insulin in
mice. However, the relevance of physiological ligands of
GPR119 to GLP-1 secretion by the L-cell currently remains
unknown.
Oleoylethanolamide (OEA) and lysophosphatidylcho-
line (LPC) are endogenously occurring fatty acid derivates
that are speciﬁc ligands of GPR119 (23,24). While LPC is
often associated with pathophysiological processes such
as atherosclerosis (25), OEA is found in a variety of
tissues, including the intestinal epithelium, under physio-
logical conditions (26). OEA is synthesized in vivo from
membrane phospholipids through an N-acylphosphati-
dylethanolamine (NAPE)-phospholipase D (PLD)-depen-
dent pathway (27); OEA can also be degraded into oleic
acid and ethanolamide by the naturally occurring enzyme
fatty acid amide hydrolase (FAAH), which is also ex-
pressed by the intestinal epithelium (28,29). Intestinal
OEA levels are known to decrease during fasting and
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1058 DIABETES, VOL. 58, MAY 2009increase upon refeeding, and OEA administration to rats
reduces food intake, suggesting a role for OEA in the
regulation of satiety (26,30–32). As OEA was ﬁrst identi-
ﬁed as a ligand for the intranuclear peroxisome prolifera-
tor–activated receptor (PPAR) , it has been generally
assumed that the appetite reduction is dependent on
PPAR activation (33). However, as GLP-1 is known to
induce satiety, we hypothesized that OEA may also stim-
ulate GLP-1 secretion from the intestinal L-cells in a
GPR119-dependent fashion.
RESEARCH DESIGN AND METHODS
Cell models. The murine (m) GLUTag L-cell line was cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) containing 25 mmol/l glucose and supple-
mented with 10% FBS; the medium was changed every 2–3 days and cells were
passaged by trypsinization and reseeding at a 1:3 dilution (17,34,35). The
human (h) NCI-H716 L-cell line was obtained from the American Type Culture
Collection (Manassas, VA). Cells were grown in suspension in RPMI-1640
supplemented with 10% FBS (35,36). Fetal rat intestinal cultures (FRICs) were
prepared by enzymatic dispersal of term fetal intestines from 19 to 20 days’
pregnant Wistar rats, and cells were maintained overnight in DMEM contain-
ing 25 mmol/l glucose, 10% FBS, and penicillin-streptomycin, as previously
reported (15,17,35,37). All three models of the intestinal L-cell have been
validated with respect to the regulation of GLP-1 secretion, such that GLP-1 is
secreted in response to known secretagogues, including muscarinic/cholin-
ergic agonists, leptin and long-chain fatty acids in all models, as well as
glucose-dependent insulinotropic peptide (GIP) in the rodent cells (17,34–38).
In vitro experiments. mGLUTag cells were plated in poly-D-lysine–coated
24-well culture plates and grown to 80% conﬂuence. For experiments with
hNCI-H716 cells, adhesion of the cells was initiated by plating on Matrigel
matrix (Becton Dickinson, Bedford, MA) in DMEM medium, supplemented
with 10% FBS, 2 days before the experiment, as described (35,38). FRIC cells
were investigated the day after cell dispersal and plating. Adenosine 3,5-
cyclic monophosphate (cAMP) responses to OEA were determined by wash-
ing mGLUTag cells with Hanks’ balanced salt solution followed by treatment
for 30 min with FBS-free medium containing 1% DMSO alone (negative
control), 10 mol/l forskolin (positive control), or 10–15 mol/l OEA, as
previously described (39). To prevent cAMP degradation, all media contained
10 mol/l 3-isobutyl-1-methylxanthine (Sigma-Aldrich, Oakville, ON, Canada).
Cells were then extracted in ethanol for radioimmunoassay (RIA) of cAMP
content. Secretion experiments were performed as described (17,34–36). In
brief, mGLUTag, hNCI-H716, and FRIC cells were washed and then incubated
for 2 h with FBS-free DMEM containing 1% DMSO alone (negative control), 10
mol/l forskolin (Sigma-Aldrich), or 1 mol/l GIP (positive controls)
(Bachem, Torrance, CA) or with different concentrations of OEA, palmi-
toylethanolamide (PEA), or LPC (all from Sigma-Aldrich). Some cells were
preincubated for 30 min with 10 mol/l or 30 mol/l H89 (Sigma-Aldrich) to
inhibit protein kinase A (PKA) or with 1 mol/l URB597 (Calbiochem,
Mississauga, ON, Canada), an FAAH inhibitor (29). DMSO was used as a
solvent to prepare stock solutions of fatty acid derivates and inhibitors. For
secretion experiments, medium and cells were collected separately and
peptides were extracted by reversed-phase adsorption using C18 silica car-
tridges (Sep-Pak; Waters Scientiﬁc, Mississauga, ON, Canada), as previously
described (17,34–36), for RIA of GLP-1 content. GLP-1 secretion was calcu-
lated as total GLP-1 content of medium normalized for the total amount of
GLP-1 in the medium plus cells. Average basal secretion of mGLUTa,
hNCI-H716, and FRIC cells was 3.4  0.3% (n  31), 2.7  0.4% (n  28), and
2.86  0.6% (n  4), respectively, of total GLP-1. No changes in total GLP-1
content were found under any of the experimental conditions (data not
shown).
Small interfering RNA transfection. mGLUTag cells were plated in a
24-well plate, as described above. Scrambled small interfering RNA (siRNA)
(control) and two siRNAs targeting murine GPR119 coding sequences were
purchased from Ambion (Austin, TX). Transfection was performed by 5-h
incubation in Opti-Mem medium using 20 pmol/l siRNA and 1 l Lipo-
fectamine 2000 (Invitrogen, Burlington, ON, Canada) as instructed by the
manufacturer. Cells were allowed to recover for 2 days before cAMP and/or
secretion experiments. Transfection efﬁciency was quantiﬁed by real-time
RT-PCR. In brief, total RNA was extracted from mGLUTag cells using an
RNeasy kit as instructed by the manufacturer (Qiagen, Mississauga, ON,
Canada) and subjected to reverse transcription using SuperScript II and
random hexamers (Invitrogen), followed by real-time PCR using TaqMan gene
expression assays (Applied Biosystems, Foster City, CA) for GPR119
(Mm00731497_s1) and 18S (Hs99999901_s1; endogenous control). Relative
quantiﬁcation of GPR119 mRNA expression was calculated using the 		 cycle
threshold method (40).
In vitro assays. Viability of the mGLUTag cells after treatment was deter-
mined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) (Sigma-Aldrich) assay, as reported (17). Cells were plated in poly-D-
lysine–coated 96-well plates and treated for 2 h with medium containing 1%
DMSO alone (control), 5 mmol/l H2O2 (positive control), or fatty acid derivates
or inhibitors at concentrations used for the secretion experiment, after which
the MTT reaction was carried out. The resulting absorbance was measured at
570 nm; higher absorbance correlates with cell viability and lower absorbance
with cell death. cAMP was measured by RIA of ethanol extracts as described
(39) (Biomedical Technologies, Stoughton, MA). RIA for COOH-terminal
GLP-1 immunoreactivity was conducted using an established lab assay
(17,34–36).
As there is currently no good GPR119 antiserum commercially available,
GPR119 expression was determined by RT-PCR. Human jejunum and colon
total RNA was purchased from Ambion, and human placental RNA was a kind
gift from Dr. J.R. Challis (University of Toronto, Toronto, ON, Canada). Total
RNA from mGLUTag, hNCI-H716, and FRIC cells, as well as from rodent
tissues, was extracted as described above. The primer pairs used for ampli-
ﬁcation of human GPR119 were described by Soga et al. (23) and for mouse
GPR40 and GPR120 by Iakoubov et al. (17); all other primer pairs were
designed using PrimerQuest (IDT, Coralville, IA) (sequences are shown in
Table 1). PCR were carried out at 57°C for 35 cycles, and PCR without RNA
template was used as the negative control. Products were analyzed by agarose
gel electrophoresis and visualized with ethidium bromide.
In vivo experiments. In vivo animal protocols were approved by the
University of Toronto Animal Care Committee. Male Wistar rats (200–300 g)
were obtained from Charles River Laboratories (St. Constant, QC, Canada)
and maintained on a standard laboratory diet with free access to water under
a 12-h light-dark schedule. Following an overnight fast, rats were anesthetized
with isoﬂurane (Baxter, Mississauga, ON, Canada). One hour before blood
sampling, some rats were intraperitoneally injected with 3 mg/kg URB597 to
inhibit FAAH (29,41). URB597 alone did not affect the levels of glucose,
TABLE 1
PCR primers
Gene (GenBank
accession no.) Primers (5–3) Position
Amplicon
(bp)
m/rGPR119 (NM_181751) TGATGGTGTTGGCCTTTGCTTCAC 328–351 666
TGGTAAAGGCAGCATTTGTGGCAG 993–970
hGPR119 (NM_178471) TCTCGGCCCACACAGAAGA 208–226 62
GCTGCGGAGGAAGTGACAAA 269–250
mGPR40 (NM_194057) TCTGATCTCCTACTGGCCATCACT 151–175 608
AGGTCCGGGTTTATGAAACTAGCC 734–758
hGPR40 (NM_005303) TTCAGCCTCTCTCTCCTGCTCTTT 550–573 328
TTCTTGCCGCACACACTGTCTTCA 877–854
mGPR120 (NM_181748) TTTCTTCTCGGATGTCAAGGGCGA 126–149 638
TCCGCGATGCTTTCGTGATCTGTA 763–740
hGPR120 (NM_181745) TCGATTTGCACACTGATTTGGCCC 630–653 408
AAATGTGAAGGCCACCACCCAGAA 1,037–1,014
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without URB597 injection were combined. The carotid artery was cannulated
for blood sampling and the jugular vein for injections. To prevent bioactive
GLP-1 degradation by dipeptidylpeptidase (DPP) IV, rats received 5 mg/kg
Sitagliptin (Januvia; MSD Sharp & Dohme, Haar, Germany), a selective
inhibitor of DPP-IV (10,42), intravenously 30 min before blood collection.
Some rats also received a femoral vein cannula for continuous infusion of
37.5% glucose to maintain glycemia at 13 mmol/l for at least 30 min. The
glucose infusion rate was adjusted based on frequent (every 5–10 min) blood
glucose measurements, as described in Goh et al. (43). Rats undergoing a
hyperglycemic clamp were not pretreated with Sitagliptin in order to reduce
the number of variables that might affect glycemia. The abdominal cavity of all
rats was then opened and a 10-cm section of the distal ileum was cleansed by
perfusion with saline and tied off to create a luminally distinct compartment
that retained vascular perfusion. Subsequent to collection of the basal blood
sample at t  0 min, either the luminal compartment was ﬁlled with 2 ml of 10
mol/l OEA or vehicle (0.9% saline/10% Tween 80; Sigma-Aldrich), or 5 mg/kg
OEA or vehicle (0.9% saline/10% Tween 80) was administered intravenously,
and additional blood samples were collected at 5, 15, 30, and 60 min. All
samples (1 ml each) were collected into 10% (vol/vol) Trasylol (5,000 Kalikrein
inactivating units/ml; Bayer, Toronto, ON, Canada), EDTA (12 mg/ml), and
diprotin A (a DPP-IV inhibitor, 68 mg/ml; Sigma-Aldrich), and plasma was
stored at 
80°C until analysis. Plasma glucose levels were analyzed on a
Beckman Analyzer II (Beckman, Fullerton, CA), and plasma insulin levels
were measured by enzyme-linked immunosorbent assay (Crystal Chem,
Downers Grove, IL) in normoglycemic animals and by RIA (Millipore, Bil-
lerica, MA) in hyperglycemic animals due to the wider insulin detection range.
Plasma levels of bioactive GLP-1 were determined by electrochemilumines-
cence-based detection assay (Meso Scale Discovery, Gaithersburg, MD).
Statistical analyses. All results are expressed as means  SE. Area under
the curve (AUC) was determined using the trapezoidal rule, and the data are
expressed per min. Statistical analysis was performed using SAS software
(SAS Institute, Cary, NC). One- and two-way ANOVA was followed by
Student’s t test or n-1 custom hypotheses post hoc tests, as appropriate. To
reduce interassay variations, some data were normalized to basal levels.
Signiﬁcance was assumed at P  0.05.
RESULTS
Expression of GPR40, GPR119, and GPR120. RT-PCR
for rodent GPR119 mRNA transcripts was performed on
total RNA extracted from mGLUTag and FRIC cells, as
well as from mouse ileum and rat colon tissue. As shown
in Fig. 1A, GPR119 mRNA was detected in both rodent
L-cell models, as well as in the intestinal samples. Addi-
tionally, GPR119 mRNA was detected in the hNCI-H716
cells and in human colon and placental tissue (Fig. 1B). In
contrast to previous reports (22), we did not detect
GPR119 mRNA in human jejunum, possibly due to a low
number of L-cells in this tissue (11). Consistent with our
previous ﬁndings (17), mRNA transcripts for both GPR40
and GPR120 were detected in the mGLUTag cells, and
both receptor mRNAs were also found to be expressed in
the hNCI-H716 cells (Fig. 1C).
OEA induces GLP-1 secretion in vitro. Possible effects
of GPR119 receptor activation on GLP-1 secretion were
ﬁrst investigated in mGLUTag cells. Release of GLP-1 was
increased to 3.1  0.4–fold of basal values by treatment
with forskolin, a direct activator of adenylyl cyclase and
strong L-cell secretagogue (34). OEA (5–20 mol/l), a
known ligand of GPR119 (24), signiﬁcantly increased
GLP-1 secretion to a maximum of 2.1  0.2–fold of basal
levels at 10 mol/l (P  0.001) (Fig. 2A). The same
concentrations of PEA, a saturated fatty acid ethanol-
amide (16:0) that is a very weak agonist of GPR119 (23,24),
did not increase GLP-1 secretion from mGLUTag cells.
Importantly, OEA treatment did not affect the viability of
the GLUTag cells (Fig. 2B). In contrast, although LPC
treatment of mGLUTag cells at concentrations reported to
activate GPR119 (10–15 mol/l) also enhanced GLP-1
release (to a maximum of 10.4  0.5–fold of control values;
data not shown), LPC was found to markedly reduce cell
viability by up to 60.0  6.8% compared with control cells
(P  0.05 and P  0.001) (Fig. 2B); LPC was, therefore, not
used in further experiments. The effects of OEA on GLP-1
secretion were also conﬁrmed in hNCI-H716 and FRIC
cells (Fig. 2C and D), wherein OEA treatment signiﬁcantly
increased GLP-1 secretion to 2.6  0.2– and 5.8  2.5–fold
of basal levels at 10 mol/l (P  0.001 and P  0.01),
respectively. Interestingly, higher concentrations of OEA
were associated with diminished GLP-1 release in all cell
models, suggestive of desensitization.
To verify the activity of GPR119 in the L-cell, mGLUTag
and hNCI-H716 cells were treated with a speciﬁc GPR119
FIG. 1. Expression of GPR119 mRNA in L-cell models. A: Total RNA
from mGLUTag cells, FRICs, and murine intestinal tissues was ana-
lyzed for expression of GPR119 mRNA by RT-PCR. B: Total RNA from
hNCI-H716 cells, human intestinal tissues, and human placenta was
analyzed for expression of GPR119 mRNA by RT-PCR. C: Total RNA
from mGLUTag cells and hNCI-H716 cells was analyzed for expression
of GPR40 and GPR120 mRNA by RT-PCR. All products were separated
on agarose gels and visualized with ethidium bromide, with the molec-
ular-size ladder on the left. Negative controls did not include RNA
template. The anticipated band sizes of products are indicated in base
pairs (bp).
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GLP-1 secretion by both cell lines to 2.1  0.2– and 2.9 
0.5–fold of basal values (P  0.01 for mGLUTag and P 
0.05 for hNCI-H716 cells) (Fig. 3), demonstrating that
GPR119 is functional and can initiate GLP-1 secretion in
these cells. To determine possible function of the other
fatty acid receptors expressed in the L-cell lines GPR40
and GPR120 (Fig. 1C), both mGLUTag and hNCI-H716
cells were also treated with the combined GPR40/GPR120
agonist GW9508 (10 mol/l) (24). Consistent with previous
ﬁndings from our group (17), GPR40 and GPR120 were not
found to be involved in GLP-1 secretion from mGLUTag
cells, as treatment with GW9508 did not increase GLP-1
secretion (Fig. 3). In contrast, GW9508 increased GLP-1
secretion by hNCI-H716 cells to 4.5  0.6–fold of basal
values (P  0.01), providing indication for a role of GPR40
and/or GPR120 in human L-cells.
Prevention of OEA degradation with URB597 signiﬁcantly
increased OEA-induced GLP-1 secretion to 3.2  0.4–
and 3.3  0.3–fold of control values at 10 and 15 mol/l
OEA in mGLUTag cells (P  0.001 compared with URB597
alone and P  0.01–0.001 compared with OEA treatment
without URB597) (Fig. 4A), as well as in hNCI-H716 cells
(to 3.5  0.2– and 5.5  0.7–fold of control values at 10 and
15 mol/l OEA (P  0.001 compared with URB597 alone
and P  0.05–0.001 compared with OEA treatment without
URB597) (Fig. 4B). These ﬁndings indicate that degrada-
tion by FAAH limits the effects of OEA on GLP-1 secretion
in both of the intestinal L-cell lines utilized.
OEA signals through a PKA- and GPR119-dependent
mechanism. As ligand binding to GPR119 leads to activa-
tion of adenylyl cyclase, increased production of cAMP,
and enhanced PKA activity (24), mGLUTag cells were ﬁrst
examined for cAMP responses to OEA (10–15 mol/l) and
GIP, which is known to signal through cAMP- and PKA-
dependent pathways (positive control) (44). OEA treat-
ment alone caused a small but signiﬁcant increase in
intracellular cAMP to 1.11  0.03 – and 1.12  0.04–fold of
control values at 10 and 15 mol/l, respectively (P  0.05)
(Fig. 5A). This effect was enhanced when OEA degradation
FIG. 2. Effects of OEA on GLP-1 secretion. mGLUTag cells (n  9–12) (A), hNCI-H716 cells (n  8) (C), and FRIC cells (n  4) (D) were incubated
with medium alone (1% DMSO, negative control), forskolin (10 mol/l, positive control), OEA (2–20 mol/l), or PEA (10–15 mol/l, negative
control) for 2 h. GLP-1 content of media and cells was determined by RIA. B: To determine potential effects on cell viability, mGLUTag cells were
incubated with medium alone (1% DMSO, negative control), H2O2 (5 mmol/l, positive control), OEA (10–20 mol/l), or LPC (10–15 mol/l) for
2 h, followed by MTT assay (n  8–16). *P < 0.05; **P < 0.01; ***P < 0.001 vs. control.
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creased by an additional 1.3  0.04 – and 1.3  0.03–fold,
respectively (P  0.001 compared with URBB597 alone
and P  0.05–0.01 compared with OEA treatment without
URB597). Furthermore, pretreatment of the mGLUTag
cells with the PKA inhibitor H89 (10 mol/l) completely
abolished OEA (10–15 mol/l)-induced GLP-1 secretion
(Fig. 5B). Similar results were found in hNCI-H716 cells,
although an increased concentration of H89 (30 mol/l)
was required to abrogate OEA-induced GLP-1 release (Fig.
5C). H89 treatment did not affect GPR40/120-induced
GLP-1 secretion (Fig. 5C, inset), demonstrating the speci-
ﬁcity of this inhibitor for PKA-mediated signaling.
To determine whether the effects of OEA on cAMP
production and GLP-1 secretion are dependent upon
GPR119, mGLUTag cells were transfected with speciﬁc
GPR119 siRNA or scrambled siRNA (control), resulting in
23% knockdown of GPR119 mRNA, as determined by
real-time RT-PCR (Fig. 6A, inset). Despite the relatively
low level of GPR119 knockdown, OEA (10 mol/l) failed
to enhance cAMP levels in cells treated with GPR119
siRNA, whereas the cAMP response to OEA treatment was
preserved in the control cells (P  0.05) (Fig. 6A). Fur-
thermore, GPR119 knockdown led to a 45% reduction in
the GLP-1 secretory response to OEA (P  0.05) (Fig. 5B).
These data therefore provide support for a role of GPR119
and the PKA signaling pathway in OEA-induced GLP-1
secretion.
OEA enhances GLP-1 secretion in vivo. To establish
the effects of OEA on the L-cell in vivo, rats were treated
with OEA either intraluminally or intravenously. Intralu-
minal application of OEA (10 mol/l; e.g., 20 nmol/rat) to
euglycemic rats signiﬁcantly increased plasma bioactive
GLP-1 concentrations to 1.5  0.2–fold of basal values
(P  0.05) within 5 min of administration, and this
stimulation was maintained throughout the entire 60-min
time course of the experiment (Fig. 7A). Thus, the AUC for
the bioactive GLP-1 response was signiﬁcantly increased
to 1.6  0.1–fold of vehicle-infused rats (P  0.001) (Fig.
7B). In contrast, intravenous administration of OEA at a
200-fold–higher dose (e.g., 4 mol/250 g rat) than that
used intraluminally demonstrated no effect on bioactive
GLP-1 concentrations compared with rats treated with
vehicle alone. Throughout the 60-min experiment, the
plasma levels of glucose (Fig. 7C) and insulin (Fig. 7D)
remained stable at basal levels and did not differ between
treatment and control groups.
As GLP-1 is known to lose its insulinotropic effects
under normoglycemic conditions, changes in insulin levels
upon OEA treatment were also measured under hypergly-
cemic conditions. Glycemia was maintained at 13 mmol/l,
the upper physiological level in rats, for at least 30 min
before the start of OEA application and throughout the
remainder of the procedure. The basal concentration of
insulin before OEA application was 1.4  0.4 pg/ml and did
not differ between the groups. Intraluminal application of
OEA caused a 3.9  0.7–fold increase in insulin plasma
levels within 5 min of application (11.2  2.1 vs. 2.8  2.0
pg/ml in the control group; P  0.01) (Fig. 7D, inset). In
contrast, intravenous infusion of OEA did not affect insulin
levels during the entire treatment period in the hypergly-
cemic rats.
DISCUSSION
Previous studies have indicated that the fatty acid derivate
receptor GPR119 is present on pancreatic -cells and
intestinal L-cells, and its stimulation by a GPR119 agonist
increases insulin and GLP-1 secretion, respectively
(21,22,24). However, the role of physiologically occurring
ligands of GPR119, such as OEA, and the intracellular
mechanisms underlying GPR119-dependent GLP-1 secre-
tion from the intestinal L-cell have remained undeﬁned.
The results of the present study demonstrate, for the ﬁrst
time, that OEA stimulates GLP-1 secretion from both
mouse and human intestinal L-cell lines, as well as from
primary rat L-cells in vitro. Additionally, application of
OEA directly into the intestinal lumen in rats induced a
signiﬁcant and persistent increase in bioactive GLP-1
levels over 1 h, supporting the in vitro ﬁndings and
demonstrating a role for OEA as a GLP-1 secretagogue in
vivo.
FIG. 3. Effects of GPR119 and GPR40/120 agonists on GLP-1 secretion. mGLUTag (n  4) (A) and hNCI-H716 (n  4) (B) cells were incubated
with medium alone (1% DMSO, negative control), OEA (10 mol/l), the GPR119 agonist PSN632408 (10 mol/l), or the combined GPR40/GPR120
agonist GW9508 (10 mol/l) for 2 h. GLP-1 content of media and cells was determined by RIA. *P < 0.05; **P < 0.01 vs. control.
GPR119 AND GLP-1 SECRETION
1062 DIABETES, VOL. 58, MAY 2009To further establish the role of OEA in GLP-1 secretion,
the intracellular signaling mechanisms underlying its ef-
fects on the L-cell were investigated. OEA induced a small,
but signiﬁcant, increase in intracellular cAMP concentra-
tion in both the mGLUTag and hNCI-H716 cells, compara-
ble with ﬁndings in OEA-treated RINm5 and MIN6
pancreatic -cell lines (45). Furthermore, GLP-1 secretion
in OEA-treated cells was strictly dependent on PKA in
both the human and mouse L-cells, as indicated by com-
plete abrogation of the response in H89-treated cells.
These ﬁndings are consistent with studies by our lab and
others showing that increased cAMP levels, in response to
cAMP analogs as well as to secretagogues such as GIP,
stimulate GLP-1 release by the intestinal L-cell (16,34,46).
Furthermore, while initial studies on OEA identiﬁed the
intranuclear receptor PPAR and transient receptor po-
tential vanilloid type 1 (TRPV1) as targets for OEA
(27,33,47), neither of these receptors has been reported to
stimulate the cAMP/PKA signaling pathway. In contrast,
the deorphanization of GPR119 as a cAMP-linked OEA
receptor (24) implicated GPR119 as more likely target for
OEA in the intestinal L-cell. Consistent with this hypothe-
sis, treatment of human and mouse intestinal L-cells with
a GPR119-speciﬁc agonist PSN632408 signiﬁcantly in-
creased GLP-1 secretion in both cell lines. Furthermore,
transfection of mGLUTag cells with GPR119 siRNA signif-
icantly diminished both the cAMP and GLP-1 responses to
OEA. When taken together, these ﬁndings provide support
for both the presence of functional GPR119 in the intesti-
nal L-cell and the requirement for this novel G-protein–
coupled receptor in OEA-induced GLP-1 secretion.
We have previously reported that oleic acid is a strong
L-cell secretagogue, increasing GLP-1 secretion both in
vivo and in vitro (17,18,48). It is therefore interesting that
OEA is rapidly degraded to oleic acid and ethanolamide
via FAAH-dependent hydrolysis (29), thereby providing a
possible GPR119-independent mechanism underlying
OEA-induced GLP-1 secretion. Therefore, to exclude the
possible effects of oleic acid on the actions of OEA, L-cells
were pretreated with the FAAH inhibitor URB597 to
reduce OEA hydrolysis and resultant oleic acid accumula-
tion. The increase in OEA-induced GLP-1 secretion found
with URB597 treatment provides support for a direct role
of OEA, and not of oleic acid, in OEA-induced GLP-1
secretion.
While intraluminal application of OEA in vivo signiﬁ-
cantly increased GLP-1 secretion in normal rats, intrave-
nous injection of OEA at a 200-fold–higher dose failed to
increase circulating levels of bioactive GLP-1. Addition-
ally, while intraluminal OEA application clearly increased
insulin levels in hyperglycemic rats, intravenous injection
of OEA did not affect insulin levels in these animals under
either euglycemic or hyperglycemic conditions. Taken
together, this data suggests that circulating OEA does not
cause signiﬁcant increases in hormone release from either
of its known target tissues (the intestinal L-cell and the
pancreatic -cell). There are several possible explanations
for these ﬁndings. First, the volume of distribution for
OEA as a lipophilic substance should be high, therefore
increasing the concentration of OEA required for admin-
istration into the jugular vein to reach distant target
tissues at stimulatory concentrations. However, higher
levels of OEA cannot be achieved in the circulation of the
rat due to the limited solubility of OEA in solvents.
Furthermore, whether OEA is cleared through the liver
and/or lungs is unknown and may be signiﬁcant.
The actions of both OEA and a GRP119 agonist on
insulin secretion have previously been reported to be
glucose dependent (21,45), as further conﬁrmed in the
present study. Previous studies have also demonstrated
that 45% of the glucose-lowering effect of an oral GPR119
agonist given concurrently with oral glucose is mediated
through enhancement of GLP-1 release (22), suggesting
that the insulinotropic effect of GPR119 activation is
mediated both directly, through GPR119 expressed on the
-cell, and indirectly, through enhanced release of GLP-1.
Nonetheless, although both the L-cell and the -cell are
responsive to OEA, the glucose sensitivity of the -cell
response, compared with the glucose insensitivity of the
L-cell response that we have observed, suggests that oral
administration of this fatty acid derivate alone to enhance
GLP-1 secretion, without inﬂuencing insulin release, will
FIG. 4. Effect of inhibition of OEA degradation on OEA-induced GLP-1
secretion. mGLUTag (n  6–18) (A) and hNCI-H716 (n  12) (B) cells
were pretreated for 30 min with URB597 (1 mol/l) to inhibit FAAH
and prevent OEA degradation before incubation with medium alone
(1%DMSO, negative control) or OEA (10–15 mol/l) for 2 h. GLP-1
content of media and cells was determined by RIA. ***P < 0.001 vs.
control; #P < 0.05; ##P < 0.01; ###P < 0.001 vs. OEA treatment alone.
L.M. LAUFFER, R. IAKOUBOV, AND P.L. BRUBAKER
DIABETES, VOL. 58, MAY 2009 1063permit the insulin-independent biological actions of
GLP-1. In contrast, administration of OEA in the setting of
a glucose-containing meal would facilitate release of both
GLP-1 and insulin, thereby also modulating glycemic re-
sponses (22,49).
The observation of apparent desensitization in all of the
dose-response curves was unexpected, as this has not
previously been reported for GPR119. However, Gs-
coupled receptors are well established to undergo homol-
A
B
C
FIG. 5. Effect of PKA inhibition on OEA-induced GLP-1 secretion.
mGLUTag (n  6–9) (A and B) and hNCI-H716 (n  4–6) (C) cells
were pretreated for 30 min with medium alone (1% DMSO, negative
control), H89 (10 mol/l for mGLUTag and 30 mol/l for hNCI-H716),
or URB597 (1 mol/l) to inhibit PKA or FAAH, respectively, followed
by incubation with medium alone (1% DMSO, negative control), GIP (1
mol/l, positive control), or OEA (10–15 mol/l) for 2 h. C, inset:
hNCI-H716 cells were pretreated for 30 min with media alone (1%
DMSO) or with H89 (30 mol/l), followed by incubation with the
GPR40/120 agonist GW9508 (10 mol/l). cAMP content of cells and
GLP-1 content of media and cells were determined by RIA. *P < 0.05;
***P < 0.001 vs. appropriate control; #P < 0.05; ##P < 0.01; ###P <
0.001 vs. paired treatment alone.
FIG. 6. Effect of GPR119 knockdown on OEA-induced GLP-1 secretion.
mGLUTag cells were transfected with scrambled siRNA (20 pmol/l,
control) or GPR119 siRNA (20 pmol/l) 2 days before the experiment.
Cells were then incubated with medium alone (1% DMSO, negative
control) or OEA (10–15 mol/l) for 2 h. cAMP content of cells (n  6)
(A) and GLP-1 content of media and cells (n  9) (B) were determined
by RIA. A, inset: GPR119 mRNA transcript levels were determined by
quantitative RT-PCR relative to 18S transcript levels. *P < 0.05;
***P < 0.001 vs. control or vs. the  change in control cells, as
indicated by the lines. #P < 0.05 vs. OEA treatment with scrambled
siRNA.
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which hNCI-716 cells were pretreated with the GPR119
agonist PSN632408 (10 mol/l for 6 h) demonstrated a
70.9  4.6% and 50.7  11.7% decrease in subsequent OEA-
and PSN632408-induced GLP-1 secretion, respectively
(data not shown). Collectively, these ﬁndings indicate that
GPR119 may undergo homologous desensitization, a phe-
nomenon that clearly warrants further investigation.
In summary, the results of this study establish, for the
ﬁrst time, the role of GPR119 in OEA-induced GLP-1
secretion and add GPR119 to the growing list of fatty
acid–responsive pathways that function to modulate re-
lease of GLP-1, including GPR40, GPR120, and PKC.
When combined with the reported insulinotropic effects of
GPR119 agonists, these ﬁndings implicate GPR119 as a
potential pharmacological target, as well as OEA as a
nutriceutical approach to enhance GLP-1 in patients with
type 2 diabetes.
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